ONTOLOGY REPORT - ANNOTATIONS
1,2-dilauroyl-sn-glycero-3-phosphocholine
|
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
EXP |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases activity |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine
|
| G |
Lipg |
lipase, endothelial |
|
increases hydrolysis |
ISO |
18 |
71,795,150 |
71,816,056 |
RGD:6480464 |
CTD |
1-O-palmitoyl-2-O-arachidonoyl-sn-glycero-3-phosphocholine
|
| G |
Lipg |
lipase, endothelial |
|
increases hydrolysis |
ISO |
18 |
71,795,150 |
71,816,056 |
RGD:6480464 |
CTD |
1D-myo-inositol 1,4,5-trisphosphate
|
| G |
Adra1a |
adrenoceptor alpha 1A |
|
increases abundance |
ISO |
15 |
46,173,429 |
46,263,198 |
RGD:6480464 |
CTD |
| G |
Adra1a |
adrenoceptor alpha 1A |
|
multiple interactions |
ISO |
15 |
46,173,429 |
46,263,198 |
RGD:6480464 |
CTD |
| G |
Adra1b |
adrenoceptor alpha 1B |
|
increases abundance |
ISO |
10 |
28,889,092 |
28,946,889 |
RGD:6480464 |
CTD |
| G |
Adra1b |
adrenoceptor alpha 1B |
|
multiple interactions |
ISO |
10 |
28,889,092 |
28,946,889 |
RGD:6480464 |
CTD |
| G |
Adra1b |
adrenoceptor alpha 1B |
|
increases metabolic processing |
ISO |
10 |
28,889,092 |
28,946,889 |
RGD:6480464 |
CTD |
| G |
Adra1d |
adrenoceptor alpha 1D |
|
increases abundance |
ISO |
3 |
119,279,974 |
119,295,985 |
RGD:6480464 |
CTD |
| G |
Adra1d |
adrenoceptor alpha 1D |
|
multiple interactions |
ISO |
3 |
119,279,974 |
119,295,985 |
RGD:6480464 |
CTD |
| G |
Casr |
calcium-sensing receptor |
|
multiple interactions |
ISO |
11 |
66,084,169 |
66,153,292 |
RGD:6480464 |
CTD |
| G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
|
affects abundance |
ISO |
1 |
211,351,738 |
211,353,120 |
RGD:6480464 |
CTD |
| G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
|
multiple interactions |
ISO |
4 |
63,911,292 |
63,913,354 |
RGD:6480464 |
CTD |
| G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
|
increases abundance |
ISO |
4 |
63,911,292 |
63,913,354 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
multiple interactions |
EXP |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
increases abundance |
EXP |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
increases chemical synthesis |
EXP |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
multiple interactions |
EXP |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Gata4 |
GATA binding protein 4 |
|
multiple interactions |
EXP |
15 |
42,472,793 |
42,519,569 |
RGD:6480464 |
CTD |
| G |
Gata4 |
GATA binding protein 4 |
|
increases expression |
EXP |
15 |
42,472,793 |
42,519,569 |
RGD:6480464 |
CTD |
| G |
Htr2b |
5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled |
|
decreases abundance |
ISO |
9 |
84,840,026 |
84,852,984 |
RGD:6480464 |
CTD |
| G |
Inpp5a |
inositol polyphosphate-5-phosphatase A |
|
multiple interactions |
ISO |
1 |
199,187,936 |
199,395,997 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
increases expression |
EXP |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Myh7 |
myosin, heavy chain 7, cardiac muscle, beta |
|
increases expression |
EXP |
15 |
33,072,928 |
33,094,595 |
RGD:6480464 |
CTD |
| G |
Nfatc3 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 |
|
multiple interactions |
EXP |
19 |
35,907,800 |
35,982,095 |
RGD:6480464 |
CTD |
| G |
Nfatc3 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 |
|
increases expression |
EXP |
19 |
35,907,800 |
35,982,095 |
RGD:6480464 |
CTD |
| G |
Npy1r |
neuropeptide Y receptor Y1 |
|
affects abundance |
EXP |
16 |
24,747,183 |
24,756,507 |
RGD:6480464 |
CTD |
| G |
Npy2r |
neuropeptide Y receptor Y2 |
|
affects abundance |
EXP |
2 |
150,554,962 |
150,556,108 |
RGD:6480464 |
CTD |
| G |
Tnfsf4 |
tumor necrosis factor (ligand) superfamily, member 4 |
|
increases abundance |
ISO |
13 |
77,026,337 |
77,050,223 |
RGD:6480464 |
CTD |
1D-myo-inositol 1-phosphate
|
| G |
Ppargc1a |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
increases expression |
ISO |
14 |
64,278,115 |
64,370,912 |
RGD:6480464 |
CTD |
2-trans,6-trans,10-trans-geranylgeranyl diphosphate
|
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bmp2 |
bone morphogenetic protein 2 |
|
multiple interactions |
ISO |
3 |
121,372,692 |
121,381,236 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Cd40 |
CD40 molecule, TNF receptor superfamily member 5 |
|
multiple interactions |
ISO |
3 |
156,092,602 |
156,107,427 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
multiple interactions |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Col1a1 |
collagen, type I, alpha 1 |
|
multiple interactions |
ISO |
10 |
83,622,438 |
83,639,368 |
RGD:6480464 |
CTD |
| G |
Crp |
C-reactive protein, pentraxin-related |
|
multiple interactions |
ISO |
13 |
88,702,243 |
88,703,153 |
RGD:6480464 |
CTD |
| G |
Ctgf |
connective tissue growth factor |
|
multiple interactions |
ISO |
1 |
21,327,099 |
21,330,215 |
RGD:6480464 |
CTD |
| G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
multiple interactions |
EXP |
1 |
251,965,458 |
251,971,449 |
RGD:6480464 |
CTD |
| G |
Cyp7a1 |
cytochrome P450, family 7, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
5 |
19,707,159 |
19,716,856 |
RGD:6480464 |
CTD |
| G |
F3 |
coagulation factor III (thromboplastin, tissue factor) |
|
multiple interactions |
ISO |
2 |
218,371,050 |
218,382,645 |
RGD:6480464 |
CTD |
| G |
Fbxo32 |
F-box protein 32 |
|
multiple interactions |
ISO |
7 |
94,909,568 |
94,942,444 |
RGD:6480464 |
CTD |
| G |
Ggps1 |
geranylgeranyl diphosphate synthase 1 |
|
decreases activity |
ISO |
17 |
59,458,469 |
59,470,856 |
RGD:6480464 |
CTD |
| G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
multiple interactions |
ISO |
2 |
27,127,504 |
27,149,580 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
multiple interactions |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Il12b |
interleukin 12B |
|
multiple interactions |
ISO |
10 |
29,558,955 |
29,568,331 |
RGD:6480464 |
CTD |
| G |
Il1a |
interleukin 1 alpha |
|
multiple interactions |
ISO |
3 |
116,913,612 |
116,924,114 |
RGD:6480464 |
CTD |
| G |
Il1a |
interleukin 1 alpha |
|
multiple interactions |
EXP |
3 |
116,913,612 |
116,924,114 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Lep |
leptin |
|
multiple interactions |
ISO |
4 |
55,943,837 |
55,945,938 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mmp1 |
matrix metallopeptidase 1 (interstitial collagenase) |
|
multiple interactions |
ISO |
8 |
4,333,773 |
4,354,284 |
RGD:6480464 |
CTD |
| G |
Mmp1 |
matrix metallopeptidase 1 (interstitial collagenase) |
|
multiple interactions |
ISO |
8 |
4,333,773 |
4,354,284 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
EXP |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
|
decreases activity |
ISO |
3 |
75,542,211 |
75,550,793 |
RGD:6480464 |
CTD |
| G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
|
multiple interactions |
ISO |
5 |
64,713,468 |
64,753,311 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Pdgfb |
platelet-derived growth factor beta polypeptide |
|
multiple interactions |
ISO |
7 |
118,244,385 |
118,262,021 |
RGD:6480464 |
CTD |
| G |
Plat |
plasminogen activator, tissue |
|
multiple interactions |
EXP |
16 |
73,711,323 |
73,736,328 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Rac1 |
ras-related C3 botulinum toxin substrate 1 |
|
multiple interactions |
ISO |
12 |
11,380,314 |
11,400,531 |
RGD:6480464 |
CTD |
| G |
Rac1 |
ras-related C3 botulinum toxin substrate 1 |
|
multiple interactions |
ISO |
12 |
11,380,314 |
11,400,531 |
RGD:6480464 |
CTD |
| G |
Retn |
resistin |
|
multiple interactions |
ISO |
12 |
2,499,630 |
2,501,370 |
RGD:6480464 |
CTD |
| G |
Rhoa |
ras homolog family member A |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Rhoa |
ras homolog family member A |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Rhoa |
ras homolog family member A |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Rhoa |
ras homolog family member A |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Rhoa |
ras homolog family member A |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Rhoa |
ras homolog family member A |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Rhoa |
ras homolog family member A |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Rhoa |
ras homolog family member A |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Runx2 |
runt-related transcription factor 2 |
|
multiple interactions |
ISO |
9 |
11,869,234 |
12,025,219 |
RGD:6480464 |
CTD |
| G |
Sele |
selectin E |
|
multiple interactions |
ISO |
13 |
79,813,455 |
79,822,845 |
RGD:6480464 |
CTD |
| G |
Stat1 |
signal transducer and activator of transcription 1 |
|
multiple interactions |
ISO |
9 |
46,455,635 |
46,497,560 |
RGD:6480464 |
CTD |
| G |
Stat1 |
signal transducer and activator of transcription 1 |
|
increases expression |
ISO |
9 |
46,455,635 |
46,497,560 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
ISO |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
|
multiple interactions |
ISO |
2 |
113,204,303 |
113,221,550 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
2-trans,6-trans-farnesyl diphosphate
|
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bmp2 |
bone morphogenetic protein 2 |
|
multiple interactions |
ISO |
3 |
121,372,692 |
121,381,236 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
multiple interactions |
EXP |
1 |
251,965,458 |
251,971,449 |
RGD:6480464 |
CTD |
| G |
Fnta |
farnesyltransferase, CAAX box, alpha |
|
multiple interactions |
EXP |
16 |
70,440,340 |
70,458,433 |
RGD:6480464 |
CTD |
| G |
Fntb |
farnesyltransferase, CAAX box, beta |
|
multiple interactions |
EXP |
6 |
99,427,967 |
99,511,373 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
multiple interactions |
ISO |
2 |
27,127,504 |
27,149,580 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
multiple interactions |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Il12b |
interleukin 12B |
|
multiple interactions |
ISO |
10 |
29,558,955 |
29,568,331 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Kras |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog |
|
multiple interactions |
EXP |
4 |
182,869,242 |
182,895,106 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
EXP |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Rac1 |
ras-related C3 botulinum toxin substrate 1 |
|
multiple interactions |
ISO |
12 |
11,380,314 |
11,400,531 |
RGD:6480464 |
CTD |
| G |
Rhoa |
ras homolog family member A |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Rhoa |
ras homolog family member A |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Runx2 |
runt-related transcription factor 2 |
|
multiple interactions |
ISO |
9 |
11,869,234 |
12,025,219 |
RGD:6480464 |
CTD |
| G |
Sele |
selectin E |
|
multiple interactions |
ISO |
13 |
79,813,455 |
79,822,845 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
3'-CMP
|
| G |
Cdipt |
CDP-diacylglycerol--inositol 3-phosphatidyltransferase |
|
multiple interactions |
ISO |
1 |
186,153,278 |
186,157,415 |
RGD:6480464 |
CTD |
3'-phospho-5'-adenylyl sulfate
|
| G |
Nat2 |
N-acetyltransferase 2 (arylamine N-acetyltransferase) |
|
multiple interactions |
ISO |
16 |
23,855,555 |
23,876,531 |
RGD:6480464 |
CTD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
multiple interactions |
ISO |
19 |
37,251,147 |
37,266,040 |
RGD:6480464 |
CTD |
| G |
Sult1a1 |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 |
|
multiple interactions |
ISO |
1 |
185,829,205 |
185,832,725 |
RGD:6480464 |
CTD |
| G |
Sult1a1 |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 |
|
increases sulfation |
ISO |
1 |
185,829,205 |
185,832,725 |
RGD:6480464 |
CTD |
| G |
Sult1a1 |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 |
|
multiple interactions |
ISO |
1 |
185,829,205 |
185,832,725 |
RGD:6480464 |
CTD |
| G |
Sult2a1 |
sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 |
|
multiple interactions |
ISO |
1 |
75,632,632 |
75,708,022 |
RGD:6480464 |
CTD |
acetyl-CoA
|
| G |
App |
amyloid beta (A4) precursor protein |
|
affects localization |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
multiple interactions |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
Crat |
carnitine O-acetyltransferase |
|
decreases activity |
EXP |
3 |
9,447,585 |
9,461,180 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Nat1 |
N-acetyltransferase 1 (arylamine N-acetyltransferase) |
|
multiple interactions |
ISO |
16 |
23,845,894 |
23,876,528 |
RGD:6480464 |
CTD |
| G |
Nat1 |
N-acetyltransferase 1 (arylamine N-acetyltransferase) |
|
multiple interactions |
ISO |
16 |
23,845,894 |
23,876,528 |
RGD:6480464 |
CTD |
| G |
Nat1 |
N-acetyltransferase 1 (arylamine N-acetyltransferase) |
|
affects binding |
ISO |
16 |
23,845,894 |
23,876,528 |
RGD:6480464 |
CTD |
| G |
Nat2 |
N-acetyltransferase 2 (arylamine N-acetyltransferase) |
|
multiple interactions |
ISO |
16 |
23,855,555 |
23,876,531 |
RGD:6480464 |
CTD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
multiple interactions |
ISO |
19 |
37,251,147 |
37,266,040 |
RGD:6480464 |
CTD |
ADP
|
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
EXP |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
decreases secretion |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
multiple interactions |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Axl |
Axl receptor tyrosine kinase |
|
decreases response to substance |
ISO |
1 |
80,964,751 |
80,994,300 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cd40lg |
CD40 ligand |
|
increases expression |
ISO |
X |
141,925,019 |
141,937,183 |
RGD:6480464 |
CTD |
| G |
Cd40lg |
CD40 ligand |
|
multiple interactions |
ISO |
X |
141,925,019 |
141,937,183 |
RGD:6480464 |
CTD |
| G |
Cd40lg |
CD40 ligand |
|
multiple interactions |
ISO |
X |
141,925,019 |
141,937,183 |
RGD:6480464 |
CTD |
| G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
|
multiple interactions |
ISO |
4 |
43,874,852 |
44,041,870 |
RGD:6480464 |
CTD |
| G |
Chordc1 |
cysteine and histidine-rich domain (CHORD)-containing 1 |
|
multiple interactions |
ISO |
8 |
15,732,905 |
15,759,297 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
increases abundance |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
multiple interactions |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
Fga |
fibrinogen alpha chain |
|
multiple interactions |
ISO |
2 |
174,737,640 |
174,753,598 |
RGD:6480464 |
CTD |
| G |
Fga |
fibrinogen alpha chain |
|
increases secretion |
ISO |
2 |
174,737,640 |
174,753,598 |
RGD:6480464 |
CTD |
| G |
Fgb |
fibrinogen beta chain |
|
decreases secretion |
ISO |
2 |
174,768,193 |
174,775,102 |
RGD:6480464 |
CTD |
| G |
Fgb |
fibrinogen beta chain |
|
multiple interactions |
ISO |
2 |
174,768,193 |
174,775,102 |
RGD:6480464 |
CTD |
| G |
Fgg |
fibrinogen gamma chain |
|
increases secretion |
ISO |
2 |
174,727,312 |
174,734,594 |
RGD:6480464 |
CTD |
| G |
Fgg |
fibrinogen gamma chain |
|
multiple interactions |
ISO |
2 |
174,727,312 |
174,734,594 |
RGD:6480464 |
CTD |
| G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
|
multiple interactions |
ISO |
4 |
161,282,215 |
161,286,090 |
RGD:6480464 |
CTD |
| G |
Gas6 |
growth arrest specific 6 |
|
increases response to substance |
ISO |
16 |
80,900,159 |
80,930,929 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
multiple interactions |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
|
multiple interactions |
ISO |
6 |
135,413,616 |
135,419,147 |
RGD:6480464 |
CTD |
| G |
Itga2 |
integrin, alpha 2 |
|
multiple interactions |
ISO |
2 |
46,967,681 |
47,080,909 |
RGD:6480464 |
CTD |
| G |
Itga2b |
integrin, alpha 2B |
|
multiple interactions |
ISO |
10 |
91,557,086 |
91,574,194 |
RGD:6480464 |
CTD |
| G |
Itgb1bp2 |
integrin beta 1 binding protein 2 |
|
multiple interactions |
ISO |
X |
89,520,700 |
89,525,600 |
RGD:6480464 |
CTD |
| G |
Itgb3 |
integrin, beta 3 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mertk |
c-mer proto-oncogene tyrosine kinase |
|
increases response to substance |
ISO |
3 |
116,308,387 |
116,416,414 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nt5e |
5' nucleotidase, ecto |
|
decreases activity |
ISO |
8 |
93,591,630 |
93,635,481 |
RGD:6480464 |
CTD |
| G |
P2ry12 |
purinergic receptor P2Y, G-protein coupled, 12 |
|
affects response to substance |
ISO |
2 |
148,611,035 |
148,613,985 |
RGD:6480464 |
CTD |
| G |
P2ry12 |
purinergic receptor P2Y, G-protein coupled, 12 |
|
multiple interactions |
ISO |
2 |
148,611,035 |
148,613,985 |
RGD:6480464 |
CTD |
| G |
P2ry12 |
purinergic receptor P2Y, G-protein coupled, 12 |
|
multiple interactions |
ISO |
2 |
148,611,035 |
148,613,985 |
RGD:6480464 |
CTD |
| G |
P2ry12 |
purinergic receptor P2Y, G-protein coupled, 12 |
|
increases response to substance |
ISO |
2 |
148,611,035 |
148,613,985 |
RGD:6480464 |
CTD |
| G |
P2ry12 |
purinergic receptor P2Y, G-protein coupled, 12 |
|
affects response to substance |
EXP |
2 |
148,611,035 |
148,613,985 |
RGD:6480464 |
CTD |
| G |
Pdgfb |
platelet-derived growth factor beta polypeptide |
|
increases secretion |
ISO |
7 |
118,244,385 |
118,262,021 |
RGD:6480464 |
CTD |
| G |
Pdgfb |
platelet-derived growth factor beta polypeptide |
|
multiple interactions |
ISO |
7 |
118,244,385 |
118,262,021 |
RGD:6480464 |
CTD |
| G |
Pf4 |
platelet factor 4 |
|
increases secretion |
ISO |
14 |
18,812,550 |
18,813,259 |
RGD:6480464 |
CTD |
| G |
Ppbp |
pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) |
|
increases secretion |
ISO |
14 |
18,816,434 |
18,817,238 |
RGD:6480464 |
CTD |
| G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
|
multiple interactions |
ISO |
1 |
77,345,194 |
77,369,417 |
RGD:6480464 |
CTD |
| G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
|
increases glutathionylation |
EXP |
3 |
159,070,473 |
159,116,792 |
RGD:6480464 |
CTD |
| G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
|
multiple interactions |
EXP |
3 |
159,070,473 |
159,116,792 |
RGD:6480464 |
CTD |
| G |
Selp |
selectin P |
|
multiple interactions |
ISO |
13 |
79,886,614 |
79,922,180 |
RGD:6480464 |
CTD |
| G |
Selp |
selectin P |
|
multiple interactions |
ISO |
13 |
79,886,614 |
79,922,180 |
RGD:6480464 |
CTD |
| G |
Selp |
selectin P |
|
multiple interactions |
ISO |
13 |
79,886,614 |
79,922,180 |
RGD:6480464 |
CTD |
| G |
Taldo1 |
transaldolase 1 |
|
increases abundance |
ISO |
1 |
201,582,856 |
201,593,187 |
RGD:6480464 |
CTD |
| G |
Thbs1 |
thrombospondin 1 |
|
increases secretion |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Tyro3 |
TYRO3 protein tyrosine kinase |
|
increases response to substance |
ISO |
3 |
106,309,671 |
106,328,607 |
RGD:6480464 |
CTD |
ADP-D-ribose
|
| G |
Adprh |
ADP-ribosylarginine hydrolase |
|
increases hydrolysis |
ISO |
11 |
64,079,175 |
64,085,514 |
RGD:6480464 |
CTD |
| G |
Adprhl2 |
ADP-ribosylhydrolase like 2 |
|
increases hydrolysis |
ISO |
5 |
145,685,493 |
145,690,767 |
RGD:6480464 |
CTD |
| G |
Adprhl2 |
ADP-ribosylhydrolase like 2 |
|
multiple interactions |
ISO |
5 |
145,685,493 |
145,690,767 |
RGD:6480464 |
CTD |
| G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
|
multiple interactions |
EXP |
20 |
11,053,301 |
11,099,740 |
RGD:6480464 |
CTD |
| G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
|
multiple interactions |
ISO |
20 |
11,053,301 |
11,099,740 |
RGD:6480464 |
CTD |
AMP
|
| G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
|
multiple interactions |
ISO |
1 |
223,731,675 |
223,773,285 |
RGD:6480464 |
CTD |
| G |
Nudt10 |
nudix (nucleoside diphosphate linked moiety X)-type motif 10 |
|
multiple interactions |
ISO |
X |
28,682,852 |
28,686,500 |
RGD:6480464 |
CTD |
| G |
Ppargc1a |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
increases expression |
ISO |
14 |
64,278,115 |
64,370,912 |
RGD:6480464 |
CTD |
arachidonoyl-CoA
|
| G |
Ppara |
peroxisome proliferator activated receptor alpha |
|
multiple interactions |
ISO |
7 |
123,729,774 |
123,807,090 |
RGD:6480464 |
CTD |
ATP
|
| G |
Abcb11 |
ATP-binding cassette, subfamily B (MDR/TAP), member 11 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcc8 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 8 |
|
multiple interactions |
EXP |
1 |
96,622,574 |
96,703,723 |
RGD:6480464 |
CTD |
| G |
Asic2 |
acid-sensing (proton-gated) ion channel 2 |
|
multiple interactions |
EXP |
10 |
69,103,244 |
70,190,305 |
RGD:6480464 |
CTD |
| G |
Atp7b |
ATPase, Cu++ transporting, beta polypeptide |
|
increases phosphorylation |
ISO |
16 |
74,607,988 |
74,680,080 |
RGD:6480464 |
CTD |
| G |
Atp8b1 |
ATPase, aminophospholipid transporter, class I, type 8B, member 1 |
|
increases hydrolysis |
EXP |
18 |
60,748,738 |
60,829,650 |
RGD:6480464 |
CTD |
| G |
Avp |
arginine vasopressin |
|
increases secretion |
EXP |
3 |
118,205,007 |
118,206,985 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcr |
breakpoint cluster region |
|
multiple interactions |
ISO |
20 |
13,972,773 |
14,097,816 |
RGD:6480464 |
CTD |
| G |
Casp1 |
caspase 1 |
|
multiple interactions |
ISO |
8 |
2,027,976 |
2,036,872 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases expression |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
|
multiple interactions |
ISO |
4 |
43,874,852 |
44,041,870 |
RGD:6480464 |
CTD |
| G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
|
multiple interactions |
ISO |
4 |
43,874,852 |
44,041,870 |
RGD:6480464 |
CTD |
| G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
|
multiple interactions |
ISO |
4 |
43,874,852 |
44,041,870 |
RGD:6480464 |
CTD |
| G |
Comt |
catechol-O-methyltransferase |
|
multiple interactions |
ISO |
11 |
84,561,591 |
84,581,713 |
RGD:6480464 |
CTD |
| G |
Crkl |
v-crk sarcoma virus CT10 oncogene homolog (avian)-like |
|
multiple interactions |
ISO |
11 |
85,520,244 |
85,554,667 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
multiple interactions |
EXP |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
increases expression |
EXP |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Enpp7 |
ectonucleotide pyrophosphatase/phosphodiesterase 7 |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
multiple interactions |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
increases secretion |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Gja1 |
gap junction protein, alpha 1 |
|
increases export |
ISO |
20 |
35,409,815 |
35,422,262 |
RGD:6480464 |
CTD |
| G |
Hspd1 |
heat shock protein 1 (chaperonin) |
|
multiple interactions |
EXP |
9 |
53,884,193 |
53,895,043 |
RGD:6480464 |
CTD |
| G |
Hspd1 |
heat shock protein 1 (chaperonin) |
|
increases expression |
EXP |
9 |
53,884,193 |
53,895,043 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
decreases abundance |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Ins1 |
insulin 1 |
|
multiple interactions |
EXP |
1 |
258,001,134 |
258,001,688 |
RGD:6480464 |
CTD |
| G |
Ins1 |
insulin 1 |
|
multiple interactions |
ISO |
1 |
258,001,134 |
258,001,688 |
RGD:6480464 |
CTD |
| G |
Ins1 |
insulin 1 |
|
multiple interactions |
EXP |
1 |
258,001,134 |
258,001,688 |
RGD:6480464 |
CTD |
| G |
Kcnj15 |
potassium inwardly-rectifying channel, subfamily J, member 15 |
|
increases activity |
ISO |
11 |
35,577,083 |
35,594,291 |
RGD:6480464 |
CTD |
| G |
Khk |
ketohexokinase |
|
multiple interactions |
ISO |
6 |
25,428,263 |
25,438,497 |
RGD:6480464 |
CTD |
| G |
Lep |
leptin |
|
multiple interactions |
EXP |
4 |
55,943,837 |
55,945,938 |
RGD:6480464 |
CTD |
| G |
Lipe |
lipase, hormone sensitive |
|
increases activity |
ISO |
1 |
80,663,791 |
80,682,480 |
RGD:6480464 |
CTD |
| G |
Lpl |
lipoprotein lipase |
|
affects response to substance |
ISO |
16 |
22,533,105 |
22,556,905 |
RGD:6480464 |
CTD |
| G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
|
affects binding |
ISO |
8 |
68,379,074 |
68,451,554 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases activity |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases activity |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
EXP |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
increases activity |
EXP |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
increases secretion |
EXP |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mt-co3 |
mitochondrially encoded cytochrome c oxidase III |
|
increases abundance |
ISO |
MT |
8,599 |
9,382 |
RGD:6480464 |
CTD |
| G |
Nadsyn1 |
NAD synthetase 1 |
|
multiple interactions |
ISO |
1 |
204,187,585 |
204,237,424 |
RGD:6480464 |
CTD |
| G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
|
multiple interactions |
ISO |
10 |
45,850,224 |
45,874,533 |
RGD:6480464 |
CTD |
| G |
Nolc1 |
nucleolar and coiled-body phosphoprotein 1 |
|
multiple interactions |
ISO |
1 |
251,297,417 |
251,308,127 |
RGD:6480464 |
CTD |
| G |
Npy |
neuropeptide Y |
|
affects response to substance |
ISO |
4 |
78,038,013 |
78,045,187 |
RGD:6480464 |
CTD |
| G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
|
increases expression |
EXP |
7 |
140,012,807 |
140,020,590 |
RGD:6480464 |
CTD |
| G |
Oxt |
oxytocin/neurophysin 1 prepropeptide |
|
multiple interactions |
EXP |
3 |
118,194,219 |
118,195,056 |
RGD:6480464 |
CTD |
| G |
Oxt |
oxytocin/neurophysin 1 prepropeptide |
|
increases secretion |
EXP |
3 |
118,194,219 |
118,195,056 |
RGD:6480464 |
CTD |
| G |
P2rx2 |
purinergic receptor P2X, ligand-gated ion channel, 2 |
|
increases activity |
EXP |
12 |
46,485,125 |
46,488,319 |
RGD:6480464 |
CTD |
| G |
P2rx2 |
purinergic receptor P2X, ligand-gated ion channel, 2 |
|
multiple interactions |
EXP |
12 |
46,485,125 |
46,488,319 |
RGD:6480464 |
CTD |
| G |
P2rx2 |
purinergic receptor P2X, ligand-gated ion channel, 2 |
|
multiple interactions |
EXP |
12 |
46,485,125 |
46,488,319 |
RGD:6480464 |
CTD |
| G |
P2rx4 |
purinergic receptor P2X, ligand-gated ion channel 4 |
|
multiple interactions |
EXP |
12 |
34,943,900 |
34,961,551 |
RGD:6480464 |
CTD |
| G |
P2rx4 |
purinergic receptor P2X, ligand-gated ion channel 4 |
|
multiple interactions |
EXP |
12 |
34,943,900 |
34,961,551 |
RGD:6480464 |
CTD |
| G |
P2rx4 |
purinergic receptor P2X, ligand-gated ion channel 4 |
|
multiple interactions |
EXP |
12 |
34,943,900 |
34,961,551 |
RGD:6480464 |
CTD |
| G |
P2rx4 |
purinergic receptor P2X, ligand-gated ion channel 4 |
|
increases activity |
EXP |
12 |
34,943,900 |
34,961,551 |
RGD:6480464 |
CTD |
| G |
P2rx4 |
purinergic receptor P2X, ligand-gated ion channel 4 |
|
multiple interactions |
EXP |
12 |
34,943,900 |
34,961,551 |
RGD:6480464 |
CTD |
| G |
P2rx4 |
purinergic receptor P2X, ligand-gated ion channel 4 |
|
multiple interactions |
EXP |
12 |
34,943,900 |
34,961,551 |
RGD:6480464 |
CTD |
| G |
P2rx4 |
purinergic receptor P2X, ligand-gated ion channel 4 |
|
multiple interactions |
EXP |
12 |
34,943,900 |
34,961,551 |
RGD:6480464 |
CTD |
| G |
P2rx7 |
purinergic receptor P2X, ligand-gated ion channel, 7 |
|
multiple interactions |
ISO |
12 |
35,074,025 |
35,117,152 |
RGD:6480464 |
CTD |
| G |
P2rx7 |
purinergic receptor P2X, ligand-gated ion channel, 7 |
|
decreases response to substance |
ISO |
12 |
35,074,025 |
35,117,152 |
RGD:6480464 |
CTD |
| G |
P2ry1 |
purinergic receptor P2Y, G-protein coupled, 1 |
|
multiple interactions |
ISO |
2 |
150,460,361 |
150,465,855 |
RGD:6480464 |
CTD |
| G |
P2ry1 |
purinergic receptor P2Y, G-protein coupled, 1 |
|
affects activity |
ISO |
2 |
150,460,361 |
150,465,855 |
RGD:6480464 |
CTD |
| G |
P2ry1 |
purinergic receptor P2Y, G-protein coupled, 1 |
|
multiple interactions |
EXP |
2 |
150,460,361 |
150,465,855 |
RGD:6480464 |
CTD |
| G |
P2ry2 |
purinergic receptor P2Y, G-protein coupled, 2 |
|
multiple interactions |
ISO |
1 |
158,440,018 |
158,454,213 |
RGD:6480464 |
CTD |
| G |
P2ry2 |
purinergic receptor P2Y, G-protein coupled, 2 |
|
increases activity |
ISO |
1 |
158,440,018 |
158,454,213 |
RGD:6480464 |
CTD |
| G |
P2ry2 |
purinergic receptor P2Y, G-protein coupled, 2 |
|
affects activity |
ISO |
1 |
158,440,018 |
158,454,213 |
RGD:6480464 |
CTD |
| G |
P2ry2 |
purinergic receptor P2Y, G-protein coupled, 2 |
|
multiple interactions |
EXP |
1 |
158,440,018 |
158,454,213 |
RGD:6480464 |
CTD |
| G |
P2ry4 |
pyrimidinergic receptor P2Y, G-protein coupled, 4 |
|
multiple interactions |
ISO |
X |
88,589,534 |
88,590,947 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
increases expression |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
|
multiple interactions |
ISO |
2 |
118,640,277 |
118,672,440 |
RGD:6480464 |
CTD |
| G |
Pik3r1 |
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) |
|
multiple interactions |
ISO |
2 |
32,602,673 |
32,675,350 |
RGD:6480464 |
CTD |
| G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
|
increases activity |
ISO |
13 |
64,135,729 |
64,280,815 |
RGD:6480464 |
CTD |
| G |
Plau |
plasminogen activator, urokinase |
|
increases secretion |
ISO |
15 |
3,680,072 |
3,686,232 |
RGD:6480464 |
CTD |
| G |
Ppara |
peroxisome proliferator activated receptor alpha |
|
multiple interactions |
ISO |
7 |
123,729,774 |
123,807,090 |
RGD:6480464 |
CTD |
| G |
Prdx2 |
peroxiredoxin 2 |
|
increases expression |
EXP |
19 |
24,836,199 |
24,841,390 |
RGD:6480464 |
CTD |
| G |
Prkca |
protein kinase C, alpha |
|
multiple interactions |
ISO |
10 |
97,367,196 |
97,638,910 |
RGD:6480464 |
CTD |
| G |
Ralbp1 |
ralA binding protein 1 |
|
multiple interactions |
ISO |
9 |
104,617,400 |
104,653,856 |
RGD:6480464 |
CTD |
| G |
Ralbp1 |
ralA binding protein 1 |
|
multiple interactions |
ISO |
9 |
104,617,400 |
104,653,856 |
RGD:6480464 |
CTD |
| G |
Sell |
selectin L |
|
multiple interactions |
ISO |
13 |
79,827,342 |
79,845,296 |
RGD:6480464 |
CTD |
| G |
Sftpa1 |
surfactant protein A1 |
|
multiple interactions |
ISO |
16 |
17,570,887 |
17,574,389 |
RGD:6480464 |
CTD |
| G |
Sftpb |
surfactant protein B |
|
increases secretion |
ISO |
4 |
105,609,410 |
105,618,452 |
RGD:6480464 |
CTD |
| G |
Sftpb |
surfactant protein B |
|
multiple interactions |
EXP |
4 |
105,609,410 |
105,618,452 |
RGD:6480464 |
CTD |
| G |
Sftpb |
surfactant protein B |
|
increases secretion |
EXP |
4 |
105,609,410 |
105,618,452 |
RGD:6480464 |
CTD |
| G |
Sftpc |
surfactant protein C |
|
increases secretion |
EXP |
15 |
50,923,105 |
50,926,047 |
RGD:6480464 |
CTD |
| G |
Sftpc |
surfactant protein C |
|
increases secretion |
ISO |
15 |
50,923,105 |
50,926,047 |
RGD:6480464 |
CTD |
| G |
Sftpc |
surfactant protein C |
|
multiple interactions |
EXP |
15 |
50,923,105 |
50,926,047 |
RGD:6480464 |
CTD |
| G |
Sirt1 |
sirtuin 1 |
|
multiple interactions |
EXP |
20 |
25,675,302 |
25,686,494 |
RGD:6480464 |
CTD |
| G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
decreases stability |
ISO |
5 |
139,690,801 |
139,719,021 |
RGD:6480464 |
CTD |
| G |
Slc5a5 |
solute carrier family 5 (sodium iodide symporter), member 5 |
|
multiple interactions |
ISO |
16 |
19,046,200 |
19,056,281 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
increases expression |
EXP |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
affects chemical synthesis |
ISO |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Taldo1 |
transaldolase 1 |
|
increases abundance |
ISO |
1 |
201,582,856 |
201,593,187 |
RGD:6480464 |
CTD |
coenzyme A
|
| G |
Acot8 |
acyl-CoA thioesterase 8 |
|
affects hydrolysis |
ISO |
3 |
155,828,209 |
155,839,862 |
RGD:6480464 |
CTD |
dCTP
|
| G |
Dck |
deoxycytidine kinase |
|
increases metabolic processing |
ISO |
14 |
20,886,700 |
20,904,305 |
RGD:6480464 |
CTD |
| G |
Dck |
deoxycytidine kinase |
|
affects activity |
ISO |
14 |
20,886,700 |
20,904,305 |
RGD:6480464 |
CTD |
dichlorvos
|
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
increases phosphorylation |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
increases phosphorylation |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
increases acylation |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases response to substance |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
affects binding |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
affects binding |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
|
increases expression |
EXP |
1 |
223,731,675 |
223,773,285 |
RGD:6480464 |
CTD |
| G |
Anxa2 |
annexin A2 |
|
increases expression |
EXP |
8 |
73,897,618 |
73,934,041 |
RGD:6480464 |
CTD |
| G |
Apeh |
acylaminoacyl-peptide hydrolase |
|
decreases activity |
ISO |
8 |
113,353,151 |
113,362,263 |
RGD:6480464 |
CTD |
| G |
Apeh |
acylaminoacyl-peptide hydrolase |
|
decreases activity |
ISO |
8 |
113,353,151 |
113,362,263 |
RGD:6480464 |
CTD |
| G |
Apeh |
acylaminoacyl-peptide hydrolase |
|
decreases activity |
EXP |
8 |
113,353,151 |
113,362,263 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
increases secretion |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
increases secretion |
EXP |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
EXP |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
EXP |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
EXP |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Btg2 |
BTG family, member 2 |
|
increases expression |
EXP |
13 |
47,026,986 |
47,030,745 |
RGD:6480464 |
CTD |
| G |
Casp1 |
caspase 1 |
|
increases expression |
EXP |
8 |
2,027,976 |
2,036,872 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
decreases expression |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases expression |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
EXP |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
decreases activity |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
increases activity |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
increases activity |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
decreases activity |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Ces1c |
carboxylesterase 1C |
|
decreases activity |
ISO |
19 |
14,981,499 |
15,021,203 |
RGD:6480464 |
CTD |
| G |
Ces2h |
carboxylesterase 2H |
|
increases expression |
EXP |
19 |
34,910,981 |
34,925,547 |
RGD:6480464 |
CTD |
| G |
Chat |
choline O-acetyltransferase |
|
increases activity |
EXP |
16 |
7,913,026 |
7,965,985 |
RGD:6480464 |
CTD |
| G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
|
decreases expression |
EXP |
1 |
211,351,738 |
211,353,120 |
RGD:6480464 |
CTD |
| G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
|
decreases expression |
EXP |
4 |
63,911,292 |
63,913,354 |
RGD:6480464 |
CTD |
| G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
|
decreases expression |
EXP |
17 |
71,214,906 |
71,218,463 |
RGD:6480464 |
CTD |
| G |
Chrna4 |
cholinergic receptor, nicotinic, alpha 4 (neuronal) |
|
multiple interactions |
ISO |
3 |
170,171,214 |
170,185,998 |
RGD:6480464 |
CTD |
| G |
Chrnb2 |
cholinergic receptor, nicotinic, beta 2 (neuronal) |
|
multiple interactions |
ISO |
2 |
181,961,373 |
181,969,581 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
multiple interactions |
ISO |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
decreases activity |
ISO |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
decreases phosphorylation |
EXP |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Cybb |
cytochrome b-245, beta polypeptide |
|
increases expression |
EXP |
X |
25,514,572 |
25,547,181 |
RGD:6480464 |
CTD |
| G |
Cycs |
cytochrome c, somatic |
|
affects localization |
EXP |
4 |
78,825,878 |
78,827,978 |
RGD:6480464 |
CTD |
| G |
Cycs |
cytochrome c, somatic |
|
affects localization |
EXP |
4 |
78,825,878 |
78,827,978 |
RGD:6480464 |
CTD |
| G |
Cycs |
cytochrome c, somatic |
|
multiple interactions |
EXP |
4 |
78,825,878 |
78,827,978 |
RGD:6480464 |
CTD |
| G |
Dbh |
dopamine beta-hydroxylase (dopamine beta-monooxygenase) |
|
increases activity |
EXP |
3 |
6,052,706 |
6,069,826 |
RGD:6480464 |
CTD |
| G |
Dbh |
dopamine beta-hydroxylase (dopamine beta-monooxygenase) |
|
multiple interactions |
EXP |
3 |
6,052,706 |
6,069,826 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
decreases activity |
EXP |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
multiple interactions |
EXP |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
decreases activity |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Fas |
Fas cell surface death receptor |
|
decreases expression |
ISO |
1 |
238,259,443 |
238,274,745 |
RGD:6480464 |
CTD |
| G |
Faslg |
Fas ligand (TNF superfamily, member 6) |
|
decreases expression |
ISO |
13 |
77,472,950 |
77,480,210 |
RGD:6480464 |
CTD |
| G |
Gabrd |
gamma-aminobutyric acid (GABA) A receptor, delta |
|
decreases expression |
EXP |
5 |
172,203,064 |
172,214,960 |
RGD:6480464 |
CTD |
| G |
Gck |
glucokinase |
|
decreases activity |
EXP |
14 |
86,572,518 |
86,587,723 |
RGD:6480464 |
CTD |
| G |
Gck |
glucokinase |
|
increases expression |
EXP |
14 |
86,572,518 |
86,587,723 |
RGD:6480464 |
CTD |
| G |
Gsr |
glutathione reductase |
|
decreases activity |
EXP |
16 |
62,255,562 |
62,298,458 |
RGD:6480464 |
CTD |
| G |
Gsr |
glutathione reductase |
|
multiple interactions |
EXP |
16 |
62,255,562 |
62,298,458 |
RGD:6480464 |
CTD |
| G |
Gsr |
glutathione reductase |
|
decreases activity |
EXP |
16 |
62,255,562 |
62,298,458 |
RGD:6480464 |
CTD |
| G |
Gsr |
glutathione reductase |
|
decreases expression |
EXP |
16 |
62,255,562 |
62,298,458 |
RGD:6480464 |
CTD |
| G |
Gsr |
glutathione reductase |
|
decreases activity |
EXP |
16 |
62,255,562 |
62,298,458 |
RGD:6480464 |
CTD |
| G |
Gys2 |
glycogen synthase 2 |
|
increases activity |
EXP |
4 |
179,984,036 |
180,018,819 |
RGD:6480464 |
CTD |
| G |
Gzma |
granzyme A |
|
decreases expression |
ISO |
2 |
44,488,295 |
44,500,128 |
RGD:6480464 |
CTD |
| G |
Gzmb |
granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) |
|
decreases expression |
ISO |
15 |
35,195,075 |
35,198,506 |
RGD:6480464 |
CTD |
| G |
Gzmk |
granzyme K |
|
decreases expression |
ISO |
2 |
44,589,295 |
44,597,386 |
RGD:6480464 |
CTD |
| G |
Hdc |
histidine decarboxylase |
|
increases activity |
EXP |
3 |
114,119,316 |
114,138,107 |
RGD:6480464 |
CTD |
| G |
Hk1 |
hexokinase 1 |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
decreases expression |
EXP |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases secretion |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
decreases response to substance |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Ins1 |
insulin 1 |
|
multiple interactions |
EXP |
1 |
258,001,134 |
258,001,688 |
RGD:6480464 |
CTD |
| G |
Itgam |
integrin, alpha M |
|
increases expression |
EXP |
1 |
187,334,413 |
187,385,583 |
RGD:6480464 |
CTD |
| G |
Itgam |
integrin, alpha M |
|
increases expression |
EXP |
1 |
187,334,413 |
187,385,583 |
RGD:6480464 |
CTD |
| G |
Lcat |
lecithin cholesterol acyltransferase |
|
decreases activity |
ISO |
19 |
35,781,507 |
35,784,966 |
RGD:6480464 |
CTD |
| G |
Lcat |
lecithin cholesterol acyltransferase |
|
multiple interactions |
ISO |
19 |
35,781,507 |
35,784,966 |
RGD:6480464 |
CTD |
| G |
Lpl |
lipoprotein lipase |
|
decreases activity |
EXP |
16 |
22,533,105 |
22,556,905 |
RGD:6480464 |
CTD |
| G |
Maoa |
monoamine oxidase A |
|
decreases activity |
EXP |
X |
17,678,960 |
17,745,908 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
decreases activity |
EXP |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Map2 |
microtubule-associated protein 2 |
|
increases phosphorylation |
EXP |
9 |
65,174,376 |
65,256,003 |
RGD:6480464 |
CTD |
| G |
Map2 |
microtubule-associated protein 2 |
|
multiple interactions |
EXP |
9 |
65,174,376 |
65,256,003 |
RGD:6480464 |
CTD |
| G |
Map2 |
microtubule-associated protein 2 |
|
increases phosphorylation |
EXP |
9 |
65,174,376 |
65,256,003 |
RGD:6480464 |
CTD |
| G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
|
increases expression |
EXP |
1 |
196,629,366 |
196,866,937 |
RGD:6480464 |
CTD |
| G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
|
affects expression |
EXP |
2 |
113,069,474 |
113,128,268 |
RGD:6480464 |
CTD |
| G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
|
decreases activity |
ISO |
2 |
113,069,474 |
113,128,268 |
RGD:6480464 |
CTD |
| G |
Nefl |
neurofilament, light polypeptide |
|
decreases expression |
EXP |
15 |
47,636,303 |
47,640,176 |
RGD:6480464 |
CTD |
| G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
increases activity |
ISO |
3 |
58,366,693 |
58,394,116 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
|
decreases activity |
EXP |
12 |
2,610,552 |
2,638,753 |
RGD:6480464 |
CTD |
| G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
|
decreases activity |
EXP |
12 |
2,610,552 |
2,638,753 |
RGD:6480464 |
CTD |
| G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
|
decreases activity |
ISO |
12 |
2,610,552 |
2,638,753 |
RGD:6480464 |
CTD |
| G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
|
decreases activity |
ISO |
12 |
2,610,552 |
2,638,753 |
RGD:6480464 |
CTD |
| G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
|
decreases activity |
EXP |
12 |
2,610,552 |
2,638,753 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
multiple interactions |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
increases secretion |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
EXP |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
decreases response to substance |
EXP |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Prf1 |
perforin 1 (pore forming protein) |
|
decreases expression |
ISO |
20 |
28,658,367 |
28,663,877 |
RGD:6480464 |
CTD |
| G |
Pygb |
phosphorylase, glycogen; brain |
|
increases activity |
EXP |
3 |
141,421,421 |
141,468,094 |
RGD:6480464 |
CTD |
| G |
Pygl |
phosphorylase, glycogen, liver |
|
increases activity |
EXP |
6 |
92,298,339 |
92,341,347 |
RGD:6480464 |
CTD |
| G |
Snca |
synuclein, alpha (non A4 component of amyloid precursor) |
|
multiple interactions |
EXP |
4 |
89,613,731 |
89,722,807 |
RGD:6480464 |
CTD |
| G |
Snca |
synuclein, alpha (non A4 component of amyloid precursor) |
|
affects localization |
EXP |
4 |
89,613,731 |
89,722,807 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
decreases activity |
EXP |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
EXP |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Tap1 |
transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) |
|
increases expression |
EXP |
20 |
4,790,363 |
4,800,730 |
RGD:6480464 |
CTD |
| G |
Tat |
tyrosine aminotransferase |
|
multiple interactions |
EXP |
19 |
39,854,163 |
39,865,060 |
RGD:6480464 |
CTD |
| G |
Tat |
tyrosine aminotransferase |
|
increases expression |
EXP |
19 |
39,854,163 |
39,865,060 |
RGD:6480464 |
CTD |
| G |
Tf |
transferrin |
|
affects binding |
ISO |
8 |
108,217,774 |
108,244,487 |
RGD:6480464 |
CTD |
| G |
Tf |
transferrin |
|
affects binding |
ISO |
8 |
108,217,774 |
108,244,487 |
RGD:6480464 |
CTD |
| G |
Th |
tyrosine hydroxylase |
|
increases activity |
EXP |
1 |
203,164,253 |
203,171,506 |
RGD:6480464 |
CTD |
| G |
Th |
tyrosine hydroxylase |
|
multiple interactions |
EXP |
1 |
203,164,253 |
203,171,506 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases secretion |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
decreases expression |
EXP |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tubb5 |
tubulin, beta 5 class I |
|
increases phosphorylation |
EXP |
20 |
3,060,224 |
3,090,776 |
RGD:6480464 |
CTD |
| G |
Tubb5 |
tubulin, beta 5 class I |
|
increases phosphorylation |
EXP |
20 |
3,060,224 |
3,090,776 |
RGD:6480464 |
CTD |
| G |
Ugp2 |
UDP-glucose pyrophosphorylase 2 |
|
decreases activity |
EXP |
14 |
102,072,724 |
102,113,561 |
RGD:6480464 |
CTD |
diisopropyl fluorophosphate
|
| G |
Aadac |
arylacetamide deacetylase |
|
multiple interactions |
ISO |
2 |
149,348,935 |
149,360,181 |
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
affects binding |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
affects binding |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
EXP |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
EXP |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Ces1c |
carboxylesterase 1C |
|
decreases activity |
ISO |
19 |
14,981,499 |
15,021,203 |
RGD:6480464 |
CTD |
| G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
|
increases expression |
ISO |
1 |
205,852,800 |
205,912,972 |
RGD:6480464 |
CTD |
| G |
Hspa5 |
heat shock protein 5 |
|
decreases expression |
ISO |
3 |
13,783,825 |
13,788,022 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
|
decreases activity |
ISO |
2 |
113,069,474 |
113,128,268 |
RGD:6480464 |
CTD |
| G |
Oprm1 |
opioid receptor, mu 1 |
|
affects response to substance |
ISO |
1 |
37,535,416 |
37,779,392 |
RGD:6480464 |
CTD |
| G |
Oprm1 |
opioid receptor, mu 1 |
|
affects response to substance |
ISO |
1 |
37,535,416 |
37,779,392 |
RGD:6480464 |
CTD |
| G |
Pepd |
peptidase D |
|
increases hydrolysis |
ISO |
1 |
87,421,576 |
87,547,908 |
RGD:6480464 |
CTD |
| G |
Pepd |
peptidase D |
|
increases hydrolysis |
ISO |
1 |
87,421,576 |
87,547,908 |
RGD:6480464 |
CTD |
| G |
Pepd |
peptidase D |
|
increases hydrolysis |
ISO |
1 |
87,421,576 |
87,547,908 |
RGD:6480464 |
CTD |
| G |
Plg |
plasminogen |
|
multiple interactions |
ISO |
1 |
42,782,464 |
42,825,149 |
RGD:6480464 |
CTD |
| G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
|
decreases activity |
ISO |
12 |
2,610,552 |
2,638,753 |
RGD:6480464 |
CTD |
| G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
|
affects response to substance |
ISO |
12 |
2,610,552 |
2,638,753 |
RGD:6480464 |
CTD |
| G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
|
decreases activity |
ISO |
12 |
2,610,552 |
2,638,753 |
RGD:6480464 |
CTD |
| G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
|
decreases activity |
EXP |
12 |
2,610,552 |
2,638,753 |
RGD:6480464 |
CTD |
| G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
|
decreases activity |
ISO |
12 |
2,610,552 |
2,638,753 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases hydrolysis |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases hydrolysis |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Rbfox3 |
RNA binding protein, fox-1 homolog (C. elegans) 3 |
|
decreases expression |
EXP |
10 |
108,492,172 |
108,635,296 |
RGD:6480464 |
CTD |
| G |
Rgn |
regucalcin (senescence marker protein-30) |
|
increases hydrolysis |
ISO |
X |
13,037,171 |
13,052,846 |
RGD:6480464 |
CTD |
| G |
Tf |
transferrin |
|
affects binding |
ISO |
8 |
108,217,774 |
108,244,487 |
RGD:6480464 |
CTD |
| G |
Tf |
transferrin |
|
affects binding |
ISO |
8 |
108,217,774 |
108,244,487 |
RGD:6480464 |
CTD |
| G |
Xdh |
xanthine dehydrogenase |
|
multiple interactions |
EXP |
6 |
21,417,685 |
21,590,015 |
RGD:6480464 |
CTD |
| G |
Xdh |
xanthine dehydrogenase |
|
increases expression |
EXP |
6 |
21,417,685 |
21,590,015 |
RGD:6480464 |
CTD |
dioleoyl phosphatidylcholine
|
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
EXP |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Lcat |
lecithin cholesterol acyltransferase |
|
affects binding |
ISO |
19 |
35,781,507 |
35,784,966 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
dipalmitoyl phosphatidylglycerol
|
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
farnesyl diphosphate
|
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bmp2 |
bone morphogenetic protein 2 |
|
multiple interactions |
ISO |
3 |
121,372,692 |
121,381,236 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
multiple interactions |
EXP |
1 |
251,965,458 |
251,971,449 |
RGD:6480464 |
CTD |
| G |
Fnta |
farnesyltransferase, CAAX box, alpha |
|
multiple interactions |
EXP |
16 |
70,440,340 |
70,458,433 |
RGD:6480464 |
CTD |
| G |
Fntb |
farnesyltransferase, CAAX box, beta |
|
multiple interactions |
EXP |
6 |
99,427,967 |
99,511,373 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
multiple interactions |
ISO |
2 |
27,127,504 |
27,149,580 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
multiple interactions |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Il12b |
interleukin 12B |
|
multiple interactions |
ISO |
10 |
29,558,955 |
29,568,331 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Kras |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog |
|
multiple interactions |
EXP |
4 |
182,869,242 |
182,895,106 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
EXP |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Rac1 |
ras-related C3 botulinum toxin substrate 1 |
|
multiple interactions |
ISO |
12 |
11,380,314 |
11,400,531 |
RGD:6480464 |
CTD |
| G |
Rhoa |
ras homolog family member A |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Rhoa |
ras homolog family member A |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Runx2 |
runt-related transcription factor 2 |
|
multiple interactions |
ISO |
9 |
11,869,234 |
12,025,219 |
RGD:6480464 |
CTD |
| G |
Sele |
selectin E |
|
multiple interactions |
ISO |
13 |
79,813,455 |
79,822,845 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
FMN
|
| G |
Rfk |
riboflavin kinase |
|
increases abundance |
ISO |
1 |
220,924,547 |
220,932,059 |
RGD:6480464 |
CTD |
| G |
Slc52a3 |
solute carrier family 52, riboflavin transporter, member 3 |
|
multiple interactions |
EXP |
3 |
142,360,661 |
142,365,285 |
RGD:6480464 |
CTD |
GDP
|
| G |
Fut8 |
fucosyltransferase 8 (alpha (1,6) fucosyltransferase) |
|
multiple interactions |
ISO |
6 |
99,871,195 |
100,010,833 |
RGD:6480464 |
CTD |
| G |
Fut8 |
fucosyltransferase 8 (alpha (1,6) fucosyltransferase) |
|
decreases activity |
ISO |
6 |
99,871,195 |
100,010,833 |
RGD:6480464 |
CTD |
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
multiple interactions |
EXP |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Rab3a |
RAB3A, member RAS oncogene family |
|
affects binding |
EXP |
16 |
19,189,765 |
19,193,874 |
RGD:6480464 |
CTD |
| G |
Rab3a |
RAB3A, member RAS oncogene family |
|
multiple interactions |
EXP |
16 |
19,189,765 |
19,193,874 |
RGD:6480464 |
CTD |
GDP-beta-S
|
| G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
|
decreases activity |
ISO |
8 |
5,472,515 |
5,577,537 |
RGD:6480464 |
CTD |
geranyl diphosphate
|
| G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
multiple interactions |
ISO |
2 |
27,127,504 |
27,149,580 |
RGD:6480464 |
CTD |
| G |
Rap1a |
RAP1A, member of RAS oncogene family |
|
multiple interactions |
ISO |
2 |
200,980,324 |
201,001,561 |
RGD:6480464 |
CTD |
glutaryl-CoA
|
| G |
Acot4 |
acyl-CoA thioesterase 4 |
|
affects hydrolysis |
ISO |
6 |
108,075,508 |
108,080,792 |
RGD:6480464 |
CTD |
| G |
Acot8 |
acyl-CoA thioesterase 8 |
|
affects hydrolysis |
ISO |
3 |
155,828,209 |
155,839,862 |
RGD:6480464 |
CTD |
GMP
|
| G |
Fut8 |
fucosyltransferase 8 (alpha (1,6) fucosyltransferase) |
|
decreases activity |
ISO |
6 |
99,871,195 |
100,010,833 |
RGD:6480464 |
CTD |
isopentenyl diphosphate
|
| G |
Ccr5 |
chemokine (C-C motif) receptor 5 |
|
decreases expression |
ISO |
8 |
128,907,157 |
128,912,272 |
RGD:6480464 |
CTD |
| G |
Fdps |
farnesyl diphosphate synthase |
|
multiple interactions |
ISO |
2 |
181,138,474 |
181,177,903 |
RGD:6480464 |
CTD |
| G |
Fgf9 |
fibroblast growth factor 9 |
|
increases expression |
ISO |
15 |
37,115,068 |
37,155,652 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
increases expression |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Il2ra |
interleukin 2 receptor, alpha |
|
multiple interactions |
ISO |
17 |
78,050,491 |
78,097,802 |
RGD:6480464 |
CTD |
| G |
Il2ra |
interleukin 2 receptor, alpha |
|
increases expression |
ISO |
17 |
78,050,491 |
78,097,802 |
RGD:6480464 |
CTD |
| G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
|
multiple interactions |
ISO |
5 |
3,531,163 |
3,584,401 |
RGD:6480464 |
CTD |
| G |
Trpv3 |
transient receptor potential cation channel, subfamily V, member 3 |
|
multiple interactions |
ISO |
10 |
60,126,243 |
60,171,718 |
RGD:6480464 |
CTD |
| G |
Vdr |
vitamin D (1,25- dihydroxyvitamin D3) receptor |
|
multiple interactions |
ISO |
7 |
136,567,614 |
136,617,280 |
RGD:6480464 |
CTD |
| G |
Vdr |
vitamin D (1,25- dihydroxyvitamin D3) receptor |
|
increases expression |
ISO |
7 |
136,567,614 |
136,617,280 |
RGD:6480464 |
CTD |
lauroyl-CoA
|
| G |
Gsta1 |
glutathione S-transferase alpha 1 |
|
multiple interactions |
ISO |
9 |
20,051,501 |
20,068,146 |
RGD:6480464 |
CTD |
malonyl-CoA
|
| G |
Mlycd |
malonyl-CoA decarboxylase |
|
multiple interactions |
ISO |
19 |
49,637,193 |
49,653,016 |
RGD:6480464 |
CTD |
| G |
Ppara |
peroxisome proliferator activated receptor alpha |
|
multiple interactions |
ISO |
7 |
123,729,774 |
123,807,090 |
RGD:6480464 |
CTD |
mevinphos
|
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
|
increases activity |
EXP |
4 |
63,911,292 |
63,913,354 |
RGD:6480464 |
CTD |
| G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
|
increases activity |
EXP |
3 |
76,301,988 |
76,309,729 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
decreases response to substance |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
EXP |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nos1 |
nitric oxide synthase 1, neuronal |
|
multiple interactions |
EXP |
12 |
39,812,500 |
39,869,484 |
RGD:6480464 |
CTD |
| G |
Nos1 |
nitric oxide synthase 1, neuronal |
|
multiple interactions |
EXP |
12 |
39,812,500 |
39,869,484 |
RGD:6480464 |
CTD |
| G |
Nos1 |
nitric oxide synthase 1, neuronal |
|
increases expression |
EXP |
12 |
39,812,500 |
39,869,484 |
RGD:6480464 |
CTD |
| G |
Nos1 |
nitric oxide synthase 1, neuronal |
|
increases expression |
EXP |
12 |
39,812,500 |
39,869,484 |
RGD:6480464 |
CTD |
| G |
Nos1 |
nitric oxide synthase 1, neuronal |
|
increases expression |
EXP |
12 |
39,812,500 |
39,869,484 |
RGD:6480464 |
CTD |
| G |
Nos1 |
nitric oxide synthase 1, neuronal |
|
increases expression |
EXP |
12 |
39,812,500 |
39,869,484 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
monocrotophos
|
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
affects expression |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
multiple interactions |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
increases expression |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bbc3 |
Bcl-2 binding component 3 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2l2 |
Bcl2-like 2 |
|
decreases expression |
EXP |
15 |
32,983,165 |
32,988,018 |
RGD:6480464 |
CTD |
| G |
Bcl2l2 |
Bcl2-like 2 |
|
decreases expression |
EXP |
15 |
32,983,165 |
32,988,018 |
RGD:6480464 |
CTD |
| G |
Bcl2l2 |
Bcl2-like 2 |
|
decreases expression |
EXP |
15 |
32,983,165 |
32,988,018 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases expression |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases expression |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases expression |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases expression |
EXP |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases expression |
EXP |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases expression |
EXP |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
decreases activity |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cycs |
cytochrome c, somatic |
|
multiple interactions |
EXP |
4 |
78,825,878 |
78,827,978 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases expression |
EXP |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases activity |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
increases expression |
EXP |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
increases expression |
EXP |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
increases expression |
EXP |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
increases activity |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
increases expression |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
multiple interactions |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases activity |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases expression |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Gsr |
glutathione reductase |
|
decreases activity |
EXP |
16 |
62,255,562 |
62,298,458 |
RGD:6480464 |
CTD |
| G |
Gstp1 |
glutathione S-transferase pi 1 |
|
increases expression |
EXP |
1 |
206,627,398 |
206,629,866 |
RGD:6480464 |
CTD |
| G |
Gstp1 |
glutathione S-transferase pi 1 |
|
increases expression |
ISO |
1 |
206,627,398 |
206,629,866 |
RGD:6480464 |
CTD |
| G |
Gstp1 |
glutathione S-transferase pi 1 |
|
multiple interactions |
ISO |
1 |
206,627,398 |
206,629,866 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
decreases response to substance |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
increases expression |
EXP |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
increases expression |
EXP |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Maoa |
monoamine oxidase A |
|
decreases activity |
EXP |
X |
17,678,960 |
17,745,908 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
decreases activity |
EXP |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Mcl1 |
myeloid cell leukemia sequence 1 |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Mcl1 |
myeloid cell leukemia sequence 1 |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Mcl1 |
myeloid cell leukemia sequence 1 |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
|
affects expression |
ISO |
11 |
64,239,918 |
64,276,702 |
RGD:6480464 |
CTD |
| G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
|
multiple interactions |
ISO |
11 |
64,239,918 |
64,276,702 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
multiple interactions |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
decreases expression |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
increases expression |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Th |
tyrosine hydroxylase |
|
multiple interactions |
EXP |
1 |
203,164,253 |
203,171,506 |
RGD:6480464 |
CTD |
| G |
Th |
tyrosine hydroxylase |
|
increases activity |
EXP |
1 |
203,164,253 |
203,171,506 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases expression |
EXP |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases expression |
EXP |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
myo-inositol hexakisphosphate
|
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
decreases activity |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
decreases expression |
ISO |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
multiple interactions |
ISO |
5 |
108,908,749 |
108,916,380 |
RGD:6480464 |
CTD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
affects methylation |
ISO |
5 |
108,908,749 |
108,916,380 |
RGD:6480464 |
CTD |
| G |
Foxo1 |
forkhead box O1 |
|
multiple interactions |
ISO |
2 |
141,127,345 |
141,203,446 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
decreases activity |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
decreases activity |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mir450a |
microRNA mir-450a |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Mlh1 |
mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) |
|
multiple interactions |
ISO |
8 |
115,616,396 |
115,653,471 |
RGD:6480464 |
CTD |
| G |
Mlh1 |
mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) |
|
affects methylation |
ISO |
8 |
115,616,396 |
115,653,471 |
RGD:6480464 |
CTD |
| G |
Pdk4 |
pyruvate dehydrogenase kinase, isozyme 4 |
|
multiple interactions |
ISO |
4 |
30,235,296 |
30,245,298 |
RGD:6480464 |
CTD |
| G |
Ppargc1a |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
multiple interactions |
ISO |
14 |
64,278,115 |
64,370,912 |
RGD:6480464 |
CTD |
| G |
Prkcd |
protein kinase C, delta |
|
multiple interactions |
ISO |
16 |
5,954,218 |
5,975,743 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
affects methylation |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Rb1 |
retinoblastoma 1 |
|
decreases phosphorylation |
ISO |
15 |
53,828,881 |
53,962,099 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
EXP |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Ucp3 |
uncoupling protein 3 (mitochondrial, proton carrier) |
|
multiple interactions |
ISO |
1 |
157,896,001 |
157,909,608 |
RGD:6480464 |
CTD |
| G |
Xdh |
xanthine dehydrogenase |
|
decreases activity |
EXP |
6 |
21,417,685 |
21,590,015 |
RGD:6480464 |
CTD |
myristoyl-CoA
|
| G |
Dbi |
diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein) |
|
affects binding |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Gsta1 |
glutathione S-transferase alpha 1 |
|
multiple interactions |
ISO |
9 |
20,051,501 |
20,068,146 |
RGD:6480464 |
CTD |
| G |
Ppara |
peroxisome proliferator activated receptor alpha |
|
multiple interactions |
ISO |
7 |
123,729,774 |
123,807,090 |
RGD:6480464 |
CTD |
naled
|
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Apeh |
acylaminoacyl-peptide hydrolase |
|
decreases activity |
ISO |
8 |
113,353,151 |
113,362,263 |
RGD:6480464 |
CTD |
| G |
Apeh |
acylaminoacyl-peptide hydrolase |
|
decreases activity |
ISO |
8 |
113,353,151 |
113,362,263 |
RGD:6480464 |
CTD |
oleoyl-CoA
|
| G |
Gsta1 |
glutathione S-transferase alpha 1 |
|
multiple interactions |
ISO |
9 |
20,051,501 |
20,068,146 |
RGD:6480464 |
CTD |
| G |
Ppara |
peroxisome proliferator activated receptor alpha |
|
multiple interactions |
ISO |
7 |
123,729,774 |
123,807,090 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
palmitoyl-CoA
|
| G |
Acox1 |
acyl-CoA oxidase 1, palmitoyl |
|
increases metabolic processing |
ISO |
10 |
106,281,977 |
106,319,382 |
RGD:6480464 |
CTD |
| G |
Acox1 |
acyl-CoA oxidase 1, palmitoyl |
|
multiple interactions |
ISO |
10 |
106,281,977 |
106,319,382 |
RGD:6480464 |
CTD |
| G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
|
multiple interactions |
EXP |
1 |
205,852,800 |
205,912,972 |
RGD:6480464 |
CTD |
| G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
|
multiple interactions |
ISO |
7 |
114,552,051 |
114,562,423 |
RGD:6480464 |
CTD |
| G |
Gsta1 |
glutathione S-transferase alpha 1 |
|
multiple interactions |
ISO |
9 |
20,051,501 |
20,068,146 |
RGD:6480464 |
CTD |
| G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
|
decreases expression |
ISO |
3 |
154,459,863 |
154,482,825 |
RGD:6480464 |
CTD |
| G |
Ppara |
peroxisome proliferator activated receptor alpha |
|
multiple interactions |
ISO |
7 |
123,729,774 |
123,807,090 |
RGD:6480464 |
CTD |
| G |
Ppara |
peroxisome proliferator activated receptor alpha |
|
multiple interactions |
ISO |
7 |
123,729,774 |
123,807,090 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Shbg |
sex hormone binding globulin |
|
decreases expression |
ISO |
10 |
56,432,474 |
56,435,654 |
RGD:6480464 |
CTD |
paraoxon
|
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
increases phosphorylation |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
increases acylation |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
increases phosphorylation |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
increases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Actb |
actin, beta |
|
increases expression |
ISO |
12 |
12,047,070 |
12,050,040 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
increases expression |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
affects binding |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
decreases response to substance |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
multiple interactions |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
increases hydrolysis |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Apc |
adenomatous polyposis coli |
|
increases expression |
ISO |
18 |
26,732,147 |
26,790,383 |
RGD:6480464 |
CTD |
| G |
Arhgdia |
Rho GDP dissociation inhibitor (GDI) alpha |
|
increases expression |
ISO |
10 |
109,967,771 |
109,971,260 |
RGD:6480464 |
CTD |
| G |
Atp5b |
ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide |
|
increases expression |
ISO |
7 |
1,376,552 |
1,383,228 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
EXP |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
EXP |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
affects binding |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
EXP |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Casp12 |
caspase 12 |
|
multiple interactions |
ISO |
8 |
2,082,933 |
2,110,511 |
RGD:6480464 |
CTD |
| G |
Casp12 |
caspase 12 |
|
increases expression |
ISO |
8 |
2,082,933 |
2,110,511 |
RGD:6480464 |
CTD |
| G |
Ces1c |
carboxylesterase 1C |
|
decreases activity |
ISO |
19 |
14,981,499 |
15,021,203 |
RGD:6480464 |
CTD |
| G |
Ces1c |
carboxylesterase 1C |
|
affects response to substance |
ISO |
19 |
14,981,499 |
15,021,203 |
RGD:6480464 |
CTD |
| G |
Ces1d |
carboxylesterase 1D |
|
decreases activity |
ISO |
19 |
14,928,539 |
14,967,082 |
RGD:6480464 |
CTD |
| G |
Ces2h |
carboxylesterase 2H |
|
decreases activity |
ISO |
19 |
34,910,981 |
34,925,547 |
RGD:6480464 |
CTD |
| G |
Ces3a |
carboxylesterase 3a |
|
decreases activity |
ISO |
19 |
34,929,247 |
34,937,267 |
RGD:6480464 |
CTD |
| G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
|
decreases expression |
ISO |
1 |
211,351,738 |
211,353,120 |
RGD:6480464 |
CTD |
| G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
|
decreases expression |
ISO |
4 |
63,911,292 |
63,913,354 |
RGD:6480464 |
CTD |
| G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
|
decreases expression |
ISO |
17 |
71,214,906 |
71,218,463 |
RGD:6480464 |
CTD |
| G |
Chrna4 |
cholinergic receptor, nicotinic, alpha 4 (neuronal) |
|
multiple interactions |
EXP |
3 |
170,171,214 |
170,185,998 |
RGD:6480464 |
CTD |
| G |
Chrna4 |
cholinergic receptor, nicotinic, alpha 4 (neuronal) |
|
decreases expression |
EXP |
3 |
170,171,214 |
170,185,998 |
RGD:6480464 |
CTD |
| G |
Chrnb2 |
cholinergic receptor, nicotinic, beta 2 (neuronal) |
|
multiple interactions |
EXP |
2 |
181,961,373 |
181,969,581 |
RGD:6480464 |
CTD |
| G |
Chrnb2 |
cholinergic receptor, nicotinic, beta 2 (neuronal) |
|
decreases expression |
EXP |
2 |
181,961,373 |
181,969,581 |
RGD:6480464 |
CTD |
| G |
Clk1 |
CDC-like kinase 1 |
|
increases expression |
ISO |
9 |
57,070,825 |
57,082,043 |
RGD:6480464 |
CTD |
| G |
Clk3 |
CDC-like kinase 3 |
|
increases expression |
ISO |
8 |
61,519,196 |
61,532,816 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
multiple interactions |
ISO |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Cnr1 |
cannabinoid receptor 1 (brain) |
|
decreases activity |
ISO |
5 |
50,427,173 |
50,445,471 |
RGD:6480464 |
CTD |
| G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
|
increases expression |
ISO |
X |
94,802,078 |
94,803,097 |
RGD:6480464 |
CTD |
| G |
Dnai1 |
dynein, axonemal, intermediate chain 1 |
|
increases expression |
ISO |
5 |
58,988,981 |
59,060,130 |
RGD:6480464 |
CTD |
| G |
Eno1 |
enolase 1, (alpha) |
|
decreases expression |
ISO |
5 |
167,394,131 |
167,405,516 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
decreases activity |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Eva1b |
eva-1 homolog B |
|
increases expression |
ISO |
5 |
145,503,410 |
145,504,714 |
RGD:6480464 |
CTD |
| G |
Fas |
Fas cell surface death receptor |
|
increases expression |
ISO |
1 |
238,259,443 |
238,274,745 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Hist1h2ak |
histone cluster 1, H2ak |
|
decreases expression |
ISO |
17 |
50,436,332 |
50,436,724 |
RGD:6480464 |
CTD |
| G |
Hist2h2be |
histone cluster 2, H2be |
|
decreases expression |
ISO |
2 |
191,024,190 |
191,026,614 |
RGD:6480464 |
CTD |
| G |
Hnrnpc |
heterogeneous nuclear ribonucleoprotein C (C1/C2) |
|
increases expression |
ISO |
15 |
27,516,839 |
27,546,646 |
RGD:6480464 |
CTD |
| G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
|
decreases expression |
ISO |
6 |
135,413,616 |
135,419,147 |
RGD:6480464 |
CTD |
| G |
Hsp90ab1 |
heat shock protein 90 alpha (cytosolic), class B member 1 |
|
decreases expression |
ISO |
9 |
11,033,496 |
11,038,868 |
RGD:6480464 |
CTD |
| G |
Hspa5 |
heat shock protein 5 |
|
decreases expression |
ISO |
3 |
13,783,825 |
13,788,022 |
RGD:6480464 |
CTD |
| G |
Ica1 |
islet cell autoantigen 1 |
|
increases expression |
ISO |
4 |
33,680,878 |
33,830,443 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
decreases response to substance |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
decreases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Ilf2 |
interleukin enhancer binding factor 2 |
|
increases expression |
ISO |
2 |
182,741,739 |
182,761,593 |
RGD:6480464 |
CTD |
| G |
Lmnb2 |
lamin B2 |
|
increases expression |
ISO |
7 |
10,303,626 |
10,326,068 |
RGD:6480464 |
CTD |
| G |
LOC680322 |
similar to Histone H2A type 1 |
|
decreases expression |
ISO |
17 |
50,119,480 |
50,119,866 |
RGD:6480464 |
CTD |
| G |
Manea |
mannosidase, endo-alpha |
|
increases expression |
ISO |
5 |
41,577,651 |
41,590,456 |
RGD:6480464 |
CTD |
| G |
Mcl1 |
myeloid cell leukemia sequence 1 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Mcl1 |
myeloid cell leukemia sequence 1 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Mcl1 |
myeloid cell leukemia sequence 1 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Mdm4 |
Mdm4 p53 binding protein homolog (mouse) |
|
increases expression |
ISO |
13 |
45,895,832 |
45,931,421 |
RGD:6480464 |
CTD |
| G |
Med16 |
mediator complex subunit 16 |
|
increases expression |
ISO |
7 |
11,311,063 |
11,323,562 |
RGD:6480464 |
CTD |
| G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
|
decreases activity |
ISO |
2 |
113,069,474 |
113,128,268 |
RGD:6480464 |
CTD |
| G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
|
decreases activity |
ISO |
2 |
113,069,474 |
113,128,268 |
RGD:6480464 |
CTD |
| G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
|
decreases activity |
ISO |
2 |
113,069,474 |
113,128,268 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
multiple interactions |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Orm1 |
orosomucoid 1 |
|
increases expression |
EXP |
5 |
80,325,042 |
80,328,194 |
RGD:6480464 |
CTD |
| G |
Phb |
prohibitin |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Pnliprp2 |
pancreatic lipase-related protein 2 |
|
decreases activity |
ISO |
1 |
265,267,609 |
265,285,920 |
RGD:6480464 |
CTD |
| G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
|
multiple interactions |
ISO |
12 |
2,610,552 |
2,638,753 |
RGD:6480464 |
CTD |
| G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
|
decreases activity |
ISO |
12 |
2,610,552 |
2,638,753 |
RGD:6480464 |
CTD |
| G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
|
decreases activity |
ISO |
12 |
2,610,552 |
2,638,753 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
affects metabolic processing |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases hydrolysis |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases hydrolysis |
EXP |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
EXP |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases activity |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
affects metabolic processing |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases hydrolysis |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases hydrolysis |
EXP |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
affects metabolic processing |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases hydrolysis |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases hydrolysis |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases hydrolysis |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
affects metabolic processing |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases hydrolysis |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
affects metabolic processing |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases hydrolysis |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
multiple interactions |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases hydrolysis |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases hydrolysis |
EXP |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases metabolic processing |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
affects hydrolysis |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
affects response to substance |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
increases metabolic processing |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
affects metabolic processing |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pon1 |
paraoxonase 1 |
|
affects metabolic processing |
ISO |
4 |
29,936,314 |
29,964,821 |
RGD:6480464 |
CTD |
| G |
Pten |
phosphatase and tensin homolog |
|
increases expression |
ISO |
1 |
236,771,027 |
236,837,261 |
RGD:6480464 |
CTD |
| G |
Sec24d |
SEC24 family, member D (S. cerevisiae) |
|
increases expression |
ISO |
2 |
219,985,811 |
220,096,797 |
RGD:6480464 |
CTD |
| G |
Sugp2 |
SURP and G patch domain containing 2 |
|
increases expression |
ISO |
16 |
19,644,374 |
19,673,741 |
RGD:6480464 |
CTD |
| G |
Tcea1 |
transcription elongation factor A (SII) 1 |
|
increases expression |
ISO |
5 |
14,834,045 |
14,871,291 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tpm4 |
tropomyosin 4 |
|
increases expression |
ISO |
16 |
18,108,914 |
18,122,956 |
RGD:6480464 |
CTD |
| G |
Tufm |
Tu translation elongation factor, mitochondrial |
|
increases expression |
ISO |
1 |
185,631,333 |
185,634,940 |
RGD:6480464 |
CTD |
| G |
Zbtb1 |
zinc finger and BTB domain containing 1 |
|
increases expression |
ISO |
6 |
98,981,038 |
98,984,303 |
RGD:6480464 |
CTD |
| G |
Zfp36 |
zinc finger protein 36 |
|
increases expression |
ISO |
1 |
83,486,643 |
83,489,123 |
RGD:6480464 |
CTD |
| G |
Zfyve19 |
zinc finger, FYVE domain containing 19 |
|
increases expression |
ISO |
3 |
105,722,207 |
105,730,192 |
RGD:6480464 |
CTD |
phosphamidon
|
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Maoa |
monoamine oxidase A |
|
decreases activity |
EXP |
X |
17,678,960 |
17,745,908 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
decreases activity |
EXP |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
poly(guanylic acid)
|
| G |
Marco |
macrophage receptor with collagenous structure |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
prenyl diphosphate
|
| G |
Il12rb1 |
interleukin 12 receptor, beta 1 |
|
increases expression |
ISO |
16 |
19,126,653 |
19,137,584 |
RGD:6480464 |
CTD |
| G |
Tnfrsf1b |
tumor necrosis factor receptor superfamily, member 1b |
|
increases expression |
ISO |
5 |
163,666,541 |
163,697,484 |
RGD:6480464 |
CTD |
sodium phosphate
|
| G |
Ppa1 |
pyrophosphatase (inorganic) 1 |
|
increases hydrolysis |
ISO |
20 |
29,015,647 |
29,042,399 |
RGD:6480464 |
CTD |
sphinganine 1-phosphate
|
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
sphingosine 1-phosphate
|
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
increases phosphorylation |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
increases phosphorylation |
ISO |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
multiple interactions |
ISO |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Cxcr1 |
chemokine (C-X-C motif) receptor 1 |
|
decreases expression |
ISO |
9 |
73,510,488 |
73,511,537 |
RGD:6480464 |
CTD |
| G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
1 |
251,965,458 |
251,971,449 |
RGD:6480464 |
CTD |
| G |
Fn1 |
fibronectin 1 |
|
multiple interactions |
EXP |
9 |
70,702,181 |
70,771,155 |
RGD:6480464 |
CTD |
| G |
Fn1 |
fibronectin 1 |
|
increases expression |
EXP |
9 |
70,702,181 |
70,771,155 |
RGD:6480464 |
CTD |
| G |
Hgf |
hepatocyte growth factor |
|
increases expression |
ISO |
4 |
14,864,357 |
14,932,513 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
increases expression |
ISO |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Kdr |
kinase insert domain receptor |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Lama3 |
laminin, alpha 3 |
|
increases expression |
ISO |
18 |
4,030,463 |
4,121,355 |
RGD:6480464 |
CTD |
| G |
Lamb3 |
laminin, beta 3 |
|
increases expression |
ISO |
13 |
109,148,815 |
109,190,322 |
RGD:6480464 |
CTD |
| G |
Lamc2 |
laminin, gamma 2 |
|
increases expression |
ISO |
13 |
68,151,074 |
68,211,117 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Nrp1 |
neuropilin 1 |
|
multiple interactions |
ISO |
19 |
58,332,004 |
58,487,686 |
RGD:6480464 |
CTD |
| G |
Nrp2 |
neuropilin 2 |
|
multiple interactions |
ISO |
9 |
61,348,529 |
61,460,457 |
RGD:6480464 |
CTD |
| G |
Pecam1 |
platelet/endothelial cell adhesion molecule 1 |
|
increases expression |
ISO |
10 |
96,056,220 |
96,057,232 |
RGD:6480464 |
CTD |
| G |
Ppara |
peroxisome proliferator activated receptor alpha |
|
multiple interactions |
EXP |
7 |
123,729,774 |
123,807,090 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
|
multiple interactions |
EXP |
2 |
211,851,304 |
211,855,511 |
RGD:6480464 |
CTD |
| G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
|
increases response to substance |
EXP |
2 |
211,851,304 |
211,855,511 |
RGD:6480464 |
CTD |
| G |
S1pr2 |
sphingosine-1-phosphate receptor 2 |
|
multiple interactions |
ISO |
8 |
19,989,867 |
20,000,759 |
RGD:6480464 |
CTD |
| G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
|
multiple interactions |
ISO |
17 |
19,657,822 |
19,661,106 |
RGD:6480464 |
CTD |
| G |
Smpd2 |
sphingomyelin phosphodiesterase 2, neutral membrane |
|
multiple interactions |
ISO |
20 |
45,448,774 |
45,451,887 |
RGD:6480464 |
CTD |
| G |
Sphk1 |
sphingosine kinase 1 |
|
increases chemical synthesis |
ISO |
10 |
106,641,509 |
106,645,579 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
ISO |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
stearoyl-CoA
|
| G |
Gsta1 |
glutathione S-transferase alpha 1 |
|
multiple interactions |
ISO |
9 |
20,051,501 |
20,068,146 |
RGD:6480464 |
CTD |
| G |
Ppara |
peroxisome proliferator activated receptor alpha |
|
multiple interactions |
ISO |
7 |
123,729,774 |
123,807,090 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
succinyl-CoA
|
| G |
Acot4 |
acyl-CoA thioesterase 4 |
|
affects hydrolysis |
ISO |
6 |
108,075,508 |
108,080,792 |
RGD:6480464 |
CTD |
tetrachlorvinphos
|
| G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
|
multiple interactions |
ISO |
11 |
64,239,918 |
64,276,702 |
RGD:6480464 |
CTD |
| G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
|
multiple interactions |
ISO |
11 |
64,239,918 |
64,276,702 |
RGD:6480464 |
CTD |
tris(2-butoxyethyl) phosphate
|
| G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
8 |
61,793,976 |
61,805,308 |
RGD:6480464 |
CTD |
| G |
Pgr |
progesterone receptor |
|
multiple interactions |
ISO |
8 |
5,784,717 |
5,845,901 |
RGD:6480464 |
CTD |
| G |
Sult1e1 |
sulfotransferase family 1E, estrogen-preferring, member 1 |
|
decreases expression |
ISO |
14 |
21,948,475 |
21,965,541 |
RGD:6480464 |
CTD |
| G |
Sult2a1 |
sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 |
|
decreases expression |
ISO |
1 |
75,632,632 |
75,708,022 |
RGD:6480464 |
CTD |
tris(2-chloroethyl) phosphate
|
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
8 |
61,793,976 |
61,805,308 |
RGD:6480464 |
CTD |
| G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
|
increases expression |
ISO |
7 |
113,043,365 |
113,049,779 |
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
|
increases expression |
ISO |
2 |
193,500,916 |
193,507,633 |
RGD:6480464 |
CTD |
| G |
Sult1e1 |
sulfotransferase family 1E, estrogen-preferring, member 1 |
|
decreases expression |
ISO |
14 |
21,948,475 |
21,965,541 |
RGD:6480464 |
CTD |
| G |
Sult2a1 |
sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 |
|
decreases expression |
ISO |
1 |
75,632,632 |
75,708,022 |
RGD:6480464 |
CTD |
UDP
|
| G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
ISO |
14 |
18,677,129 |
18,679,175 |
RGD:6480464 |
CTD |
| G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
|
multiple interactions |
ISO |
X |
94,802,078 |
94,803,097 |
RGD:6480464 |
CTD |
| G |
Gpr17 |
G protein-coupled receptor 17 |
|
multiple interactions |
ISO |
18 |
24,374,253 |
24,375,272 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
P2ry6 |
pyrimidinergic receptor P2Y, G-protein coupled, 6 |
|
multiple interactions |
ISO |
1 |
158,381,127 |
158,406,783 |
RGD:6480464 |
CTD |
| G |
P2ry6 |
pyrimidinergic receptor P2Y, G-protein coupled, 6 |
|
affects response to substance |
ISO |
1 |
158,381,127 |
158,406,783 |
RGD:6480464 |
CTD |
UDP-alpha-D-galactose
|
| G |
Gpr17 |
G protein-coupled receptor 17 |
|
increases activity |
ISO |
18 |
24,374,253 |
24,375,272 |
RGD:6480464 |
CTD |
UDP-alpha-D-glucuronic acid
|
| G |
B3gat3 |
beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) |
|
affects binding |
ISO |
1 |
211,597,624 |
211,604,142 |
RGD:6480464 |
CTD |
| G |
B3gat3 |
beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) |
|
multiple interactions |
ISO |
1 |
211,597,624 |
211,604,142 |
RGD:6480464 |
CTD |
| G |
Ppargc1a |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
increases expression |
ISO |
14 |
64,278,115 |
64,370,912 |
RGD:6480464 |
CTD |
| G |
Ugt1a1 |
UDP glucuronosyltransferase 1 family, polypeptide A1 |
|
multiple interactions |
ISO |
9 |
87,091,241 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt2b7 |
UDP glucuronosyltransferase 2 family, polypeptide B7 |
|
multiple interactions |
ISO |
14 |
22,499,152 |
22,522,842 |
RGD:6480464 |
CTD |
UDP-D-galactose
|
| G |
Gpr17 |
G protein-coupled receptor 17 |
|
increases activity |
ISO |
18 |
24,374,253 |
24,375,272 |
RGD:6480464 |
CTD |
UDP-D-glucose
|
| G |
Gpr17 |
G protein-coupled receptor 17 |
|
increases activity |
ISO |
18 |
24,374,253 |
24,375,272 |
RGD:6480464 |
CTD |
Term paths to the root
|